Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering

Newswire.ca - Fri Mar 20, 6:41PM CDT

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

SASKATOON, SK, March 20, 2026 /CNW/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical stage life sciences company focused on the development and commercialization of novel non-opioid pharmaceutical drug candidates for pain management, is pleased to announce that it has now completed the first tranche (the "First Tranche") of its non-brokered private placement (the "Offering") of units (each a "Unit"), as  previously announced on February 24, 2026. The size of the Offering has been revised from up to C$7,000,000 (for up to 11,111,111 Units), as disclosed in the February 24, 2026 news release, to up to C$1,100,000 (for up to 1,746,031 Units).

Read more at newswire.ca

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).